In the last decade, Acenitobacter baumannii has become the center of attention for microbiologists. Even amongst the ESKAPE pathogens, whose innate ability to develop resistance to various major antibiotic classes poses a threat to the nature of the modern treatment, A.baumannii is often one of the first species to develop resistance to new drugs. Because of its ability to adapt even to those inhospitable environments which would otherwise be fatal to other pathogens, A.baumannii has emerged as one of the most dangerous pathogens known to humankind and surely worthy of every bit of consideration it is getting. To coop up with the strains of the surrounding, A.baumannii exhibits a different variety of mechanisms of resistance that helps the bacteria in its survival. With the help of genetic studies and loads of experiments, we have finally learned a great deal about the mechanisms behind Aceintobacter Baumannii tremendous ability to develop immunity against antibiotics. However, against A.baumannii multiple drug regimens are used which aid each other in killing the bacteria one way or the other. The field of genetics has helped the most in identifying the various mechanisms of resistance and of course, this knowledge will help us to discover new ways of treatment that are more efficient and beneficial in our battle against the resistant strains. The optimal treatment for the MDR has yet to be established. New data is being collected every day and this clinical data is necessary for the guidance of clinicians towards the right path for choosing the best drug therapy. The discovery of therapies along with controlled trials is essential to face this problem.